Identifying early risk of preeclampsia using blood tests
Official title: Epigenetic phenotyping from liquid biopsy for preeclampsia risk classification during the first trimester
Funded at Kanona, INC. · NIH-10822733 · Data updated 2026-11-12
This study is looking at how to identify the risk of preeclampsia early in pregnancy by checking the mother's blood for certain genetic markers, which could help doctors take action sooner and improve health for both moms and babies.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Kanona, INC. NIH-funded |
| Lab location | 1 site (Scotch Plains, United States) |
| Project start | January 15, 2024 |
| Project end | December 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $306,223 |
| NIH project number | 1R41HL172464-01 |
| Project ID | NIH-10822733 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are pregnant individuals in their first trimester who may be at risk for developing preeclampsia.
✕Less likely to help
Patients who are not pregnant or those who are in later stages of pregnancy may not benefit from this research.
What this research studies
This research investigates how to classify the risk of preeclampsia, a serious pregnancy condition, during the first trimester by analyzing genetic material found in the mother's blood. The approach involves examining circulating placental derivatives, such as RNA and cell-free DNA, to detect early signs of complications. By improving risk assessment methods, the research aims to enhance early intervention strategies, potentially leading to better outcomes for both mothers and their babies.
Why it matters
Potential benefit: If successful, this research could lead to earlier identification of women at risk for preeclampsia, allowing for timely interventions that could improve maternal and fetal health.
How similar studies have gone: Other research has shown promise in using similar approaches to assess pregnancy complications, indicating potential for success in this area.
Where this research is happening
-
Kanona, INC.
Scotch Plains, United States Active
Researchers
- Principal investigator: Reichel, Jonathan — Kanona, INC.
- Study coordinator: Reichel, Jonathan
Related research
Other NIH-funded projects on the same topics.
-
Ethical, multimodal AI for predicting preeclampsia risk in early pregnancy
A data-driven AI tool uses early-pregnancy information from medical records, ultrasound, and notes to predict preeclampsia risk and support safer pregnancy care.
-
Placental support cells and fetal red blood cell quality in preeclampsia
This grant studies how placental support cells in preeclampsia affect the development and quality of a baby’s red blood cells.
-
Epigenetic clues to preeclampsia in pregnancy
This grant explores how epigenetic changes and paternal factors may contribute to preeclampsia, a condition that can affect pregnancy health.
-
Towards a blood-based test using nanophotonic exosomes to screen and diagnose liver cancer
A new blood test using tiny particles shed by liver cancer cells aims to screen for hepatocellular carcinoma earlier and more accurately.
-
Environmental air pollutants linked to preeclampsia risk in pregnancy
This study looks at whether common air pollutants called PAHs increase the risk of preeclampsia during pregnancy.
-
Dynamic risk prediction and subtyping of hypertensive disorders in pregnancy
A digital health approach uses AI to spot early warning signs of preeclampsia and gestational hypertension from pregnancy data, so clinicians can tailor care for pregnant people.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.